Total Utang marang Modal Personalis Corp (PSNL)

Personalis - logo grafis emiten PSNL

The debt-to-equity ratio for Personalis, Inc. stands at 0.17, illustrating the company's financial stability. Personalis, Inc. integrates ESG standards into cancer diagnostics, strictly adhering to bioethics and environmental guidelines. The risks associated with a narrow specialization in sequencing are mitigated by an innovative liquid biopsy IT platform. Treatment efficacy also relies on the rapid express delivery of biomaterials to laboratories.

personalis.com (PSNL): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 30.10.2026
Produk dadi Personalis, Inc.

Scaling genomic tumor profiling requires significant capital expenditures in infrastructure. This metric is calculated as the ratio of total liabilities to net equity, measuring the business's degree of reliance on external borrowings. The investor assesses whether the debt load serves as a tool for expansion or a risk of insolvency. The stability of this proportion distinguishes strategic growth from financial instability. The dynamics of the debt-to-equity ratio reflect the current resource management discipline of Personalis, Inc. (PSNL).

Analisis pesaing Personalis, Inc.

ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Erasca Inc (ERAS) - Rasio Total Utang marang Ekuitas|DCTH: Total Utang marang Modal|Utang marang Modal Y-mAbs Corp (YMAB)|Utang marang Ekuitas Aura Biosciences, Inc.|CADL: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas ARAY (Accuray)|SLS (sellaslifesciences.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ACTU (Actuate Therapeutics, Inc)|CTOR - Rasio Total Utang marang Ekuitas|HURA: Rasio Total Utang marang Ekuitas|TARA - Total Utang marang Modal|Fate Therapeutics (FATE) - Utang marang Ekuitas|Aadi Bioscience - Rasio Kabeh Utang marang Dana Pribadi|TCRX (TScan Therapeutics Inc) - Total Utang marang Modal|Utang marang Modal Champions Oncology Corp CSBR|Utang marang Ekuitas XBiotech Inc. (XBIT)|CVM: Utang Agregat marang Ekuitas|Total Utang marang Modal OSTX (OS Therapies)|radiopharmtheranostics.com (RADX) - Utang marang Modal|ARTV - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi ANL (Adlai Nortye Ltd.)|Veru Inc. (VERU) - Utang marang Ekuitas|TPST - Koefisien Total Utang marang Modal|Utang marang Ekuitas Xilio Therapeutics Inc|Utang marang Modal Enochian BioSciences RENB|Utang marang Ekuitas Mural Oncology plc (MURA)|kairospharma.com - Rasio Utang marang Ekuitas|Total Utang marang Modal OKUR (OnKure Therapeutics)|Total Utang marang Modal CytoMed Therapeutics Ltd GDTC|CRIS - Utang marang Ekuitas|APLM: Utang marang Ekuitas|THAR: Total Utang marang Modal|ADVB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Genprex, Inc.|Calidi Bio (CLDI) - Koefisien Total Utang marang Modal|Rasio Total Utang marang Ekuitas SBFM (Sunshine Biopharma, Inc.)|XBIO (xeneticbio.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLRX (Salarius)|Koefisien Total Utang marang Modal Kitov Pharma (PPBT)|AONC - Utang marang Ekuitas|BGNE (beigene.com) - Rasio Utang marang Ekuitas|CKPT: Total Utang marang Modal|Rasio Total Utang marang Ekuitas elevationoncology.com|Rasio Total Utang marang Ekuitas ICAD|Ikena (IKNA) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Notable Labs, Ltd. (NTBL)|VIRX: Utang Agregat marang Ekuitas|Utang marang Ekuitas MorphoSys MOR|Koefisien Total Utang marang Modal NAYA Biosciences Inc (NAYA)|AAPGV - Utang marang Ekuitas